Search Result

Results for "

ischemic disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (1) Adrenergic Receptor (4) Amyloid-β (2) Angiotensin-converting Enzyme (ACE) (4) Apoptosis (7) ATP Synthase (1) Calcium Channel (2) DAPK (1) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (1) HIF/HIF Prolyl-Hydroxylase (2) iGluR (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) MDM-2/p53 (1) Na+/H+ Exchanger (NHE) (1) Proteasome (1) STAT (2) TRP Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (18) Endocrinology (3) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (12)
Oligonucleotides:	Antisense Oligonucleotides (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153595

DAPK-IN-2	DAPK	Cardiovascular Disease
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases .

HY-66010

Cinepazide Maleate MD-67350	Calcium Channel	Cardiovascular Disease
Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide Maleate is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al .

HY-P1061

Colivelin Maximum Cited Publications 46 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-P1061A

Colivelin TFA Maximum Cited Publications 46 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-W017540

Cyclocreatine 1 Publications Verification	ATP Synthase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-160509

BTB 06061	TRP Channel	Neurological Disease
BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease .

HY-66010A

Cinepazide	Calcium Channel	Cardiovascular Disease
Cinepazide is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al .

HY-B0203

Nebivolol R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-U00278

Deloxolone (3β,20β)-3-(3-Carboxy-1-oxopropoxy)olean-9(11)-en-29-oic acid	Others	Inflammation/Immunology
Deloxolone has the potential for inflammatory, ischemic and proliferative diseases treatment.

HY-120553

B-355252	Apoptosis	Neurological Disease
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .

HY-B1392A

Esmolol	Adrenergic Receptor	Cardiovascular Disease
Esmolol is a potent and cardio-selective β-adrenergic blocker. Esmolol shows cardioprotection. Esmolol has the potential for the research of tachycardia with ischemic heart disease .

HY-160604

Remacemide FPL 12924; PR 934-423; FPL 13592	iGluR	Neurological Disease
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .

HY-N8598

Caulophine	Others	Cardiovascular Disease
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .

HY-162165

Neuroprotective agent 4	Others	Neurological Disease
Neuroprotective agent 4 (compound 24a) is a novel and effective small molecule antioxidant. Neuroprotective agent 4 has a neuroprotective effect. Neuroprotective agent 4 can be used in the study of ischemic stroke and related diseases .

HY-161703

2-Hydroxy-3′-O-methyladenosine	Adenosine Deaminase	Cardiovascular Disease
2-Hydroxy-3′-O-methyladenosine is a synthetic intermediate product that can be used in the research of ischemic heart disease, cerebrovascular disease, kidney disease, inflammatory allergies and other diseases. 2-phenylamino-N6,2'-O-dimethyladenosine produced from 2-Hydroxy-3′-O-methyladenosine is an inhibitor of adenosine deaminase with a Ki of 13 nM .

HY-B0203AR

Nebivolol hydrochloride (Standard) R 065824 hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-139331

20S Proteasome-IN-1	Proteasome	Neurological Disease Inflammation/Immunology Cancer
20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .

HY-110315

Ischemin sodium	Apoptosis MDM-2/p53 Epigenetic Reader Domain	Cardiovascular Disease
Ischemin sodium is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC₅₀ value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .

HY-E70231

Defibrase, deinagkistrodonacutus	Others	Cardiovascular Disease
Defibrase, deinagkistrodonacutus is a proteolytic enzyme extraction of Agkistrodon halys venom. Defibrase can be used for degradation of fibrinogen. Defibrase can exacerbate myosin-induced EAM (experimental autoimmune myositis). Defibrase can be used for degradation of fibrinogen. Defibrase is commonly used for research of acute ischemic cerebrovascular disease, thromboangiitis obliterans, deep phlebitis and sudden deafness .

HY-136055

(S,R,S)-AHPC-C5-COOH VH032-C5-COOH	E3 Ligase Ligand-Linker Conjugates HIF/HIF Prolyl-Hydroxylase	Cancer
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a K_d of 185 nM, has the potential for the study of anemia and ischemic diseases .

HY-143333

Nrf2 activator-3	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research .

HY-112678

TM6008	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
TM6008 is a potent and orally active prolyl hydroxylase (PHD) inhibitor. TM6008 chelats transition metal (copper) and inhibits the autoxidation of ascorbic acid with an IC₅₀ value is 0.57 μM. TM6008 exerts organ protection against ischemia in vivo and can be used for cerebrovascular disease research .

HY-W704968

2-Oxo-zoniporide hydrochloride	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
2-Oxo-zoniporide hydrochloride is an oral active sodium-hydrogen exchanger type 1 (NHE-1) inhibitor and can be used for study of myocardial ischemic injury .

HY-B0378A

Moexipril hydrochloride RS-10085	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects ^- .

HY-117281

Moexipril	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease Neurological Disease
Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-117281S1

Moexipril-d3	Apoptosis Angiotensin-converting Enzyme (ACE) Isotope-Labeled Compounds	Cardiovascular Disease Neurological Disease
Moexipril-d₃ is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-B0378AR

Moexipril hydrochloride (Standard)	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril (hydrochloride) (Standard) is the analytical standard of Moexipril (hydrochloride). This product is intended for research and analytical applications. Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .

HY-N9602

6,7,4'-Trihydroxyflavanone	Others	Inflammation/Immunology
6,7,4'-Trihydroxyflavanone is a compound with multiple pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic and protective T-cells from METH-induced deactivation. 6,7,4'-Trihydroxyflavanone has shown potential protective effects in neurotoxicity studies and can be used to inhibit patients with neurodegenerative diseases caused by METH. 6,7,4'-Trihydroxyflavanone inhibits METH-induced neurotoxicity by upregulating the Nrf2/HO-1 and PI3K/Akt/mTOR signaling pathways. 6,7,4'-Trihydroxyflavanone can also induce Nrf2 nuclear translocation and HO-1 expression, further enhancing its protective effect on neuronal cells .

Cat. No.	Product Name

HY-L088

Angiogenesis-Related Compound Library	2,189 compounds
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 2,189 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Angiogenesis-Related Compound Library

2,189 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 2,189 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Cat. No.	Product Name	Target	Research Area